SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, today announced receipt of a U.S. patent for its blood collection and transport preservative. The patent, entitled USE OF DIAZOLIDINYL UREA FOR ANTI-CLUMPING OF BIOLOGICAL SAMPLES, was issued as U.S. Patent No. 9,040,255.
The granted patent covers Biocept’s blood collection preservative contained in the tube for collecting patient blood used for circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic analysis at Biocept. The patented collection preservative significantly reduces clumping of cells that may interfere with their capture when using microchannels and other devices for up to 96 hours, preserving specimen integrity in order to allow Biocept to perform testing for patients worldwide. Other preservatives for blood are limited to 24 hours, therefore compromising the ability to offer many types of testing globally. This patent further expands the intellectual property protection of the tools Biocept uses for its liquid biopsy analysis.
“This patent is highly complementary to the multiple patents we hold on our microchannel technology both in the U.S. and overseas, and further protects the unique solutions we are bringing to oncology and laboratory medicine to address challenges associated with surgical biopsies," said Biocept’s Senior Vice President and Chief Science Officer Lyle Arnold, PhD.
“With broad IP protection across our platform, we are well positioned to capitalize on the movement to the liquid biopsy, which can save money for the healthcare system and most importantly help patients qualify for treatments that can save or prolong their life,” added Biocept’s President and Chief Executive Officer Michael Nall.
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers OncoCEE-GA™ for gastric cancer, OncoCEE-BR™ for breast cancer and OncoCEE-LU™ for non-small cell lung cancer, and plans to introduce CLIA-validated tests for colorectal, prostate and other solid tumors in the near term.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to economic benefits for the healthcare system, improvement of outcomes, our impact on diagnostic strategies and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.